German Court Issues Preliminary Injunction Against amedes Fetalis® Test for Infringement of Non-Invasive Prenatal Screening ...
October 24 2016 - 4:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) and Laboratory Corporation of
America® Holdings (LabCorp®) (NYSE:LH), the world’s leading
healthcare diagnostics company, today announced that on October 5,
2016, the Düsseldorf Regional Federal Court in Germany issued a
preliminary injunction order against amedes MVZ Trägergesellschaft
G�ttingen mbH and a related company (collectively “amedes”). The
order requires amedes to immediately stop performing the Fetalis®
non-invasive prenatal screening test in Germany, which is based on
technology from Ariosa Diagnostics, Inc.
The Application for the Grant of a Preliminary Injunction
against amedes was filed by Sequenom, Inc., a wholly-owned
subsidiary of LabCorp®, as patent owner of EP 0 994 963. The patent
relates to the detection of cell-free fetal DNA for non-invasive
prenatal screening. Illumina exclusively licenses the patent in the
field of in vitro diagnostics.
Illumina and Sequenom have significant intellectual property
rights in the area of non-invasive prenatal screening and will
continue to enforce those rights when appropriate. This suit adds
to prior patent infringement suits filed against others in Europe,
Australia and the United States.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
About LabCorp®
Laboratory Corporation of America® Holdings (NYSE:LH), an
S&P 500 company, is the world’s leading healthcare diagnostics
company, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and develops
technology-enabled solutions to change the way care is provided.
With net revenue in excess of $8.5 billion in 2015, LabCorp’s
50,000 employees serve clients in 60 countries. To learn more about
LabCorp, visit www.labcorp.com, and to learn more about Covance
Drug Development, visit www.covance.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024006293/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243ir@illumina.comorMedia:Tina
Amirkiai858-882-6822pr@illumina.comorDavid Robertson, Europe,
Middle East and Africa+44 1223
824909drobertson@illumina.comorLaboratory Corporation of America®
HoldingsInvestor Relations:Paul Surdez, 336-436-5076Vice President,
Investor RelationsInvestor@labcorp.comorMedia Relations:Pattie
Kushner, 336-436-8263Vice President, Corporate
CommunicationsMedia@labcorp.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024